132 results on '"Cattina F"'
Search Results
2. TEMPORAL PATTERNS OF SEVERAL IMMUNOLOGICAL PARAMETERS AS POSSIBLE INDICATORS OF IMMUNE SYSTEM EFFECTIVENESS IN ALLOGENEIC STEM CELL TRANSPLANTATION: PH-AB278
3. PROFILE OF TOLL-LIKE RECEPTORS ON MONOCYTES AND LYMPHOCYTES IN RELATION TO INFECTIOUS COMPLICATIONS AND OUTCOME IN ALLOGENEIC STEM CELL TRANSPLANTATION: PH-P499
4. EARLY AND AGGRESSIVE MANAGEMENT OF IFI IN ALLOTRANSPLANTED PATIENTS PRODUCES LOW MORBIDITY AND MORTALITY: PH-P481
5. EXTRACORPOREAL PHOTOAPHERESIS FOR THE TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE (AGVHD). A SINGLE CENTER EXPERIENCE: PH-P395
6. MULTI-GENOTYPING OF MINOR HISTOCOMPATIBILITY ANTIGENS (MHAGS) IN ALLOGENEIC STEM CELL TRANSPLANTATION AND THEIR ROLE IN DETERMINING GRAFT VERSUS HOST DISEASE (GVHD) AND GRAFT VERSUS LEUKEMIA (GVL) EFFECT: PH-P109
7. Expression of toll-like receptors on peripheral blood cells after allogeneic stem cell transplantation: ongoing results of a prospective study: P486
8. Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner?
9. Identification of a Novel Mutation Predisposing to Familial AML and MDS Syndrome By a NGS Approach
10. PB2269 PARENTERAL NUTRITION AND ACUTE GVHD IN HEMATOPOIETIC STEM CELLS TRANSPLANTATION: A PROSPECTIVE OBSERVATIONAL COHORT STUDY
11. PS1540 MULTIPARAMETRIC PREDICTIVE SCORE FOR GRAFT VERSUS HOST DISEASE (GVHD) IN PATIENTS SUBMITTED TO ALLOGENEIC STEM CELLS TRANSPLANTATION (SCT)
12. PS997 A NEW BIOMARKER OF RESPONSE TO 5-AZACITIDINE THERAPY IN MDS AND AML PATIENTS: SIRPB1
13. PF404 TUMOR-DERIVED EXOSOMES MAY BE USED AS NEW INFORMATIVE TOOL FOR THE DETECTION OF BONE MARROW RESIDUAL CML LEUKEMIC CELLS ACTIVITY
14. COMPLEX GENETIC HETEROGENEITY INFLUENCES PROGNOSIS IN ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA NEGATIVE FOR RECURRENT FUSION GENES
15. Long term outcome of ph+ cml patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era
16. Mesenchymal Stromal Cells interplay with Umbilical Cord Blood Hematopoietic Progenitor Cells for hematopoietic reconstitution. Co-culturing effects and Gene Expression Profiles
17. PI-PLCBETA1 GENE METHYLATION AND EXPRESSION AS A RELIABLE AND DYNAMIC MARKER OF CLINICAL RESPONSE TO 5-AZACYTIDINE IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROMES
18. DEREGULATED EXPRESSION OF CHECKPOINT KINASE 1 (CHK1) IN BCR-ABL-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (BCR-ABL+ ALL) SUGGESTS A NEW THERAPEUTIC TARGET
19. High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing
20. POST REMISSION SEQUENTIAL MONITORING OF MINIMAL RESIDUAL DISEASE BY WT1 Q-PCR AND MULTIPARAMETRIC FLOW CYTOMETRY PREDICTS RELAPSE AND MAY HELP TO ADDRESS THE RISK ADAPTED THERAPY IN ACUTE MYELOID LEUKEMIA PATIENTS
21. POST REMISSION MONITORING OF MINIMAL RESIDUAL DISEASE BY WT1 AND LEUKEMIA ASSOCIATED IMMUNOPHENOTYPE PREDICTS RELAPSE IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS
22. PARAMETERS OF PROTEIN METABOLISM AND THYROID FUNCTION AS PREDICTORS OF A SCORING SYSTEM FOR ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE
23. SINGLE-AGENT INHIBITION OF CHECKPOINT KINASE 1 (CHK1) AND 2 (CHK2) BY PF-0477736 (PFIZER) AS A NEW PROMISING THERAPY IN B-ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
24. SET-UP OF A MULTIPLEX PCR TO RAPIDLY DETECT IKZF1 (IKAROS) GENE BREAKPOINT DELETION IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
25. High Sensitivity Mutation Monitoring and Clonal Analysis by Ultra-Deep Amplicon Sequencing Uncover the Complexity of BCR-ABL Mutation Status in Philadelphia+ Patients Treated with Tyrosine Kinase Inhibitors
26. Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL)
27. IS PI-PLC 1 EXPRESSION A RELIABLE PREDICTOR OF RESPONSE IN LOW RISK MDS PATIENTS TREATED WITH LOW-DOSE AZACITIDINE? RESULTS OF A PROSPECTIVE MULTICENTRIC STUDY
28. Ultra-Deep Amplicon Sequencing Using Roche 454 Technology Allows High Sensitivity Bcr-Abl Kinase Domain Mutation Screening and Anticipates Emerging Mutations Leading to Resistance to Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients
29. The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients
30. PROFILE OF TOLL-LIKE RECEPTORS ON MONOCYTES AND LYMPHOCYTES IN RELATION TO INFECTIOUS COMPLICATIONS AND OUTCOME IN ALLOGENEIC STEM CELL TRANSPLANTATION
31. EARLY AND AGGRESSIVE MANAGEMENT OF IFI IN ALLOTRANSPLANTED PATIENTS PRODUCES LOW MORBIDITY AND MORTALITY
32. WT-1 FROM PERIPHERAL BLOOD PREDICTS RELAPSE IN AML PATIENTS UNDERGOING STEM CELL TRANSPLANTATION
33. MULTI-GENOTYPING OF MINOR HISTOCOMPATIBILITY ANTIGENS (MHAGS) IN ALLOGENEIC STEM CELL TRANSPLANTATION AND THEIR ROLE IN DETERMINING GRAFT VERSUS HOST DISEASE (GVHD) AND GRAFT VERSUS LEUKEMIA (GVL) EFFECT
34. EXTRACORPOREAL PHOTOAPHERESIS FOR THE TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE (AGVHD). A SINGLE CENTER EXPERIENCE
35. THE PYROSEQUENCING: A NEW PROMISING APPROACH TO PERFORM HLA TYPING AND SELECT THE STEM CELL DONOR IN A QUICKLY, SIMPLE AND ACCURATE WAY
36. AZACYTIDINE IN THE TREATMENT OF ACUTE MYELOID LEUKEMIAS RECURRING AFTER ALLOGENEIC TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
37. MULTI-GENOTYPE OF MINOR HISTOCOMPATIBILITY ANTIGENS (MHAGS) TO STUDY GRAFT VERSUS HOST DISEASE (GVHD) AND GRAFT VERSUS LEUKEMIA (GVL) EFFECTS IN ALLOGENEIC STEM CELL TRANSPLANTATION
38. A NEW PROMISING APPROACH TO PERFORM HLA TYPING IN A QUICKLY, SIMPLE AND ACCURATE WAY: THE PYROSEQUENCING
39. COMBINED EFFECTS OF MESENCHYMAL STROMAL CELLS (MSC) AND STIMULATORY CYTOKINES ON THE ex vivo GROWTH OF UMBILICAL CORD BLOOD HEMATOPOIETIC PROGENITOR CELLS (UCB-HPC)
40. CIRCULATING ENDOTHELIAL CELLS (CEC) ARE A RELIABLE AND DYNAMIC BIOMARKER OF ACUTE GVHD (AGVHD) IN PATIENTS UNDERGOING ALLOGENEIC STEM CELLS TRANSPLANTATION
41. POSSIBLE CORRELATION BETWEEN DIFFERENT TOLL-LIKE RECEPTORS, MONOCYTES, LYMPHOCYTE SUBSETS, TYPE OF INFECTIONS AND OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
42. PYROSEQUENCING IS A NEW PROMISING APPROACH TO PERFORM HLA TYPING IN A QUICKLY, SIMPLE AND ACCURATE WAY
43. PROSPECTIVE PHASE II STUDY ON 5-days AZACITIDINE (5d-AZA) FOR TREATMENT OF SYMPTOMATIC AND/OR ERYTHROPOIETIN UNRESPONSIVE PATIENTS WITH LOW/INT-1 RISK MYELODYSPLASTIC SYNDROMES
44. DYNAMICS OF EXPANSION OF TYROSINE KINASE INHIBITOR-RESISTANT MUTANTS AS ASSESSED BY DEEP SEQUENCING OF THE BCR-ABL KINASE DOMAIN: IMPLICATIONS FOR ROUTINE MUTATION TESTING
45. COMBINED EFFECTS OF MESENCHYMAL STROMAL CELLS AND STIMULATORY CYTOKINES ON THE IN VITRO GROWTH OF UCB HEMATOPOIETIC PROGENITOR CELLS
46. TOLL-LIKE RECEPTORS ON PERIPHERAL BLOOD CELLS AND ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: RESULTS OF A PROSPECTIVE STUDY
47. AZACITIDINE (AZA) FOR RELAPSED HIGH RISK MYELODYSPLASIC SYNDROME AFTER INTRABONE CORD BLOOD TRANSPLANTATION: A CASE REPORT
48. Achievement of complete remission with Ponatinib therapy for Philadelphia positive acute lymphoblastic leukemia relapsed after allogeneic stem cell transplantation: a case report
49. FOLLOW UP A LUNGO TERMINE DEI PAZIENTI CON LMC-PH+ IN RISPOSTA CITOGENETICA COMPLETA CON TERAPIA INCLUDENTE INTERFERONE NELL’ERA IMATINIB - PROTOCOLLO GIMEMA CML0509
50. TOLL-LIKE RECEPTOR EXPRESSION AND INFECTIOUS COMPLICATIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.